Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial [Pediatric Oncology]
Conclusion
Alisertib 60 mg/m2 per dose for 7 days is tolerable with a standard irinotecan and temozolomide backbone and has promising response and progression-free survival rates. A phase II trial of this regimen is ongoing.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: DuBois, Marachelian, Fox, Kudgus, Reid, Groshen, Malvar, Bagatell, Wagner, Maris, Hawkins, Courtier, Lai, Goodarzian, Shimada, Czarnecki, Tsao-Wei, Matthay, Mosse Tags: Neuroblastoma, Developmental Therapeutics & Pharmacology Pediatric Oncology Source Type: research
More News: Cancer & Oncology | Drugs & Pharmacology | Neuroblastoma | Neurology | Pediatrics | Study | Temodar | Thrombocytopenia | Toxicology